The Brains of Anxious People May Perceive the World Differently

iStock
iStock

A study showed that people with generalized anxiety disorder unconsciously label harmless things as threats, which may serve to further their anxiety. These findings were published in the journal Current Biology.

Psychologists recognize several forms of clinical anxiety. The most common is generalized anxiety disorder, or GAD, in which people frequently feel very worried or anxious even when it seems like there’s nothing to worry about. Some studies have suggested that anxiety disorders may stem from a process called overgeneralization.

In overgeneralization, the brain lumps both safe and unsafe things together and labels them all unsafe. For this reason, the researchers also call this the “better safe than sorry” approach. Our brains naturally pay more attention to negative or threatening information in our environments. If anxious people perceive more threats in the world around them, it would make a lot of sense for them to be worried.

To find out if overgeneralization was involved, researchers recruited 28 people diagnosed with GAD and 16 people without anxiety and brought them into the lab. The experiment had two parts: training and testing. In the training section, study participants learned to differentiate between three different sounds. Each sound was tied to a different outcome; pressing a key could lead to winning money (the “positive” tone), losing money (the “negative” tone), or nothing (the “neutral” tone).

In the second phase of the experiment, researchers played 15 different sounds for the participants and asked them to press a key when they heard a sound they recognized from the training phase. If they guessed right, they’d win money, but if they guessed wrong, the researchers would take some of their money back.

Because of the risk of losing money, the best strategy for everyone would be a conservative one—not pressing the button much at all based on the assumption that most of the tones were new. But anxious participants were trigger-happy, believing they’d heard many of the unfamiliar tones before. The experience of winning and losing money in training had made a strong emotional impression on them, which led them to overgeneralize new information as relevant.

The researchers also administered brain scans during the testing phase. They found notable differences between anxious and non-anxious brains. While they were focused on parsing new information, anxious people showed more activation in several parts of the brain, including the amygdala, a region associated with fear and worry.

"We show that in patients with anxiety, emotional experience induces plasticity in brain circuits that lasts after the experience is over," senior co-author Rony Paz said in a press release. "Such plastic changes occur in primary circuits that later mediate the response to new stimuli, resulting in an inability to discriminate between the originally experienced stimulus and a new similar stimulus. Therefore, anxiety patients respond emotionally to such new stimuli as well, resulting in anxiety even in apparently irrelevant new situations. Importantly, they cannot control this, as it is a perceptual inability to discriminate."

Paz noted that in dangerous circumstances, the hyper-vigilance associated with anxiety might be a good thing. The problem is that most circumstances aren’t dangerous. "Anxiety traits can be completely normal, and even beneficial evolutionarily," he says. "Yet an emotional event, even minor sometimes, can induce brain changes that might lead to full-blown anxiety."

A Generic EpiPen Coming in Early 2019 Could Save You Money

Brand-name EpiPens at a Congressional hearing on the escalating cost of the drug in 2016
Brand-name EpiPens at a Congressional hearing on the escalating cost of the drug in 2016
Alex Wong/Getty Images

For an incredibly common, life-saving medication, EpiPens (epinephrine auto-injectors) are surprisingly difficult for many consumers to get ahold of. Their cost has skyrocketed in recent years from less than $100 for a pack of two to more than $600. They’ve gotten so expensive that some EMTs have resorted to using syringes to manually administer epinephrine rather than purchasing the standard auto-injectors, which are almost exclusively made by the pharmaceutical company Mylan. Generic options have been slow to come to market, but according to Business Insider, a recently approved EpiPen rival is coming in the first few months of 2019, and it could save consumers a significant chunk of change.

The drug’s developers have had an unusually hard time getting the new EpiPen alternative, called Symjepi, onto store shelves. The drug was approved in 2017, but the company, Adamis Pharmaceuticals, had trouble finding investors. Now, Novartis, the Swiss-based pharmaceutical giant that manufactures drugs like Ritalin, is releasing the drug through its Sandoz division (perhaps most famous for it role in discovering LSD in the 1930s).

Symjepi will cost $250 out-of-pocket for a pack of two doses. That’s 16.6 percent less than the Mylan-authorized generic EpiPen or Teva’s generic EpiPen, which both sell for $300. It differs a bit from its rivals, though, in that it’s a pre-filled, single-dose syringe rather than a spring-loaded auto-injector. Auto-injectors are plastic, pen-like devices that keep the needle shielded until the moment of injection, and are specifically designed to help make it easier for untrained (even squeamish) people to use in an emergency. With this version, patients will need to remove a needle cap and inject the needle. Just like the EpiPen, though, it’s designed to be injected in the upper thigh, through clothing if necessary.

If you have health insurance, the difference in cost may not matter as much for you as a consumer, depending on your plan. (I personally picked up a two-pack of Mylan-authorized generic Epipens at CVS recently for $0, using a manufacturer’s Epipen coupon to knock down what would have been a $10 copay.) But it will matter considerably for those with high-deductible plans and to insurers, which, when faced with high costs, eventually pass those costs on to the consumer either through higher co-pays or higher premiums. It also affects agencies that buy EpiPens for emergency use, like local fire departments. And since EpiPens expire after just a year, the costs add up.

However, there’s currently a shortage of EpiPens on the market, according to the FDA, making it more important than ever to have other epinephrine drugs available to those at risk for serious allergic reactions.

[h/t Business Insider]

Brain-Eating Amoeba Kills Seattle Woman Who Used Tap Water in Her Neti Pot

CDC/Dr. Govinda S. Visvesvara, Wikimedia Commons // Public domain
CDC/Dr. Govinda S. Visvesvara, Wikimedia Commons // Public domain

If you use a neti pot to clear out your sinuses, there's one important rule you should always follow: Don't fill it with tap water. Doing so could land you a sinus infection, or worse, a potentially fatal disease caused by a brain-eating amoeba. Although the latter scenario is exceptionally rare, a 69-year-old woman in Seattle died from doing just that, The Seattle Times reports. Experts are also warning that these infections could become more common as temperatures in the northern hemisphere continue to rise.

Physicians at Seattle's Swedish Medical Center initially thought the woman had a brain tumor. She was brought into the emergency room following a seizure, and a CT scan of her brain seemed to reveal a tumor-like mass. The only other known symptom she had was a red sore on her nose, which was previously misdiagnosed as rosacea. When surgeons operated on her the following day, they noticed that "a section of her brain about the size of a golf ball was bloody mush," neurosurgeon Dr. Charles Cobbs told The Seattle Times. "There were these amoeba[e] all over the place just eating brain cells. We didn't have any clue what was going on, but when we got the actual tissue we could see it was the amoeba."

She died a month later of an infection called granulomatous amoebic encephalitis (GAE), according to a recent case report published in the International Journal of Infectious Diseases. The disease is caused by a single-celled amoeba called Balamuthia mandrillaris, and it's extremely deadly. Of the 109 cases between 1974 and 2016, 90 percent were fatal.

According to the FDA, some bacteria and amoebae in tap water are safe to swallow because acid in the stomach kills them. However, when they enter the nasal cavity, they can stay alive for long periods of time and travel up to the brain, where they start eating their way through tissue and cells. Another brain-eating amoeba called Naegleria fowleri can cause a similar disease, except it acts faster and can cause death in just a few days. Although it's also rare, it's usually found in warm freshwater, and infections start by getting contaminated water up one's nose while swimming or by using a nose irrigation device filled with tap water.

Dr. Cynthia Maree, an infectious disease doctor at the Swedish Medical Center, said the changing environment could facilitate the spread of these infections. "I think we are going to see a lot more infections that we see south (move) north, as we have a warming of our environment," Maree says. Researchers say these amoebae are still little-understood. Future studies would need to be conducted to learn more about the risk factors involved.

[h/t The Seattle Times]

SECTIONS

arrow
LIVE SMARTER